STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] ARDELYX, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ardelyx, Inc. (ARDX) reported an insider equity transaction by its Chief Business Officer, Mike Kelliher. On 11/21/2025, he sold 5,560 shares of common stock at a price of $5.5369 per share. The company states these shares were sold automatically upon the vesting of restricted stock units to cover applicable withholding taxes, rather than as a discretionary sale.

Following this transaction, Kelliher directly beneficially owns 271,181 shares of Ardelyx common stock. The filing is a Form 4 submitted for one reporting person and reflects a routine tax-related sale connected to equity compensation.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kelliher Mike

(Last) (First) (Middle)
C/O ARDELYX, INC.
400 FIFTH AVENUE, SUITE 210

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARDELYX, INC. [ ARDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2025 S(1) 5,560 D $5.5369 271,181 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
Remarks:
Chief Business Officer
/s/ Elizabeth Grammer, Attorney-in-Fact for Mike Kelliher 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ardelyx (ARDX) report in this Form 4?

The Chief Business Officer, Mike Kelliher, reported selling 5,560 shares of Ardelyx common stock on 11/21/2025.

At what price were the Ardelyx (ARDX) shares sold in the reported transaction?

The 5,560 Ardelyx shares were sold at a price of $5.5369 per share.

Why were the Ardelyx (ARDX) shares sold by the insider?

The filing explains the sale was an automatic sell-to-cover to pay applicable withholding taxes upon the vesting of restricted stock unit awards.

How many Ardelyx (ARDX) shares does the insider own after this transaction?

After the transaction, Mike Kelliher beneficially owns 271,181 shares of Ardelyx common stock directly.

What is Mike Kelliher’s role at Ardelyx (ARDX)?

Mike Kelliher is identified in the filing as Ardelyx’s Chief Business Officer.

Is this Ardelyx (ARDX) filing for one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person.
Ardelyx

NASDAQ:ARDX

ARDX Rankings

ARDX Latest News

ARDX Latest SEC Filings

ARDX Stock Data

1.39B
235.83M
2.45%
70.91%
8.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
FREMONT